Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
ANTICOAGULATION TRAINING COURSE
The King’s Thrombosis Centre runs this training course twice a year, which was developed to meet the educational needs of healthcare professionals involved in anticoagulation management. Click here to download an application form and agenda.
EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click the image to access the site.
Latest News
-
Anticoagulation news items. Week commencing 2nd March to 25th May 2020
Impact of direct oral anticoagulant off‐label doses on clinical outcomes of atrial fibrillation patients: A systematic review British Journal of Clinical PharmacologyThis analysis of 75 observational studies (mainly retrospective) found…
-
Anticoagulation news items. Week commencing 3rd, 10th, 17th and 24th February 2020
Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Thrombosis ResearchDatabase review (1.5 million hospitalisations, and 3731 major haemorrhages) found, after accounting for differences in…
-
Anticoagulation news items. Week commencing 13th, 20th and 27th January 2020
Revised SPC: Pradaxa (dabigatran) capsules electronic Medicines compendium SPC now advises that concomitant administration with glecaprevir/pibrentasvir is contraindicated owing to increased risk of bleeding due to increased dabigatran levels. Also,…
